

# Formulary Update

November 2023

The following changes to the [Adult Medicines Formulary](#) have been agreed during the ADTC or sub-committee meetings since October 2023. Additions and deletions of medicines are based on submitted formulary appeals, new drug assessment requests or formulary section reviews. Changes in preferred brands are based on decisions by Prescribing Management Groups.

ADTC decisions relating to SMC assessments are published in alternate months and can be accessed [here](#)

| <b>Deletions</b>                               | <b>Indication</b>                           | <b>Adult Medicines Formulary entry/ rationale</b>    |
|--|---|--|
| <b>Additions</b>                               | <b>Indication</b>                           | <b>Adult Medicines Formulary entry/ rationale</b>    |
| Benilexa® levonorgestrel IUD                   | Is now the preferred brand in primary care. | 7.3.2.3 Preferred List Formulary new drug assessment |
| <b>Changes in preferred medicines or brand</b> | <b>New preferred medicines or brand</b>     | <b>Adult Medicines Formulary entry / rationale</b>   |
| <b>Other changes</b>                           | <b>Changes made</b>                         | <b>Adult Medicines Formulary entry/ rationale</b>    |